ADCT vs. NTLA, AMPH, WVE, AUPH, ARDX, ELVN, VERV, NAGE, DYN, and CDTX
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs. Its Competitors
Intellia Therapeutics (NASDAQ:NTLA) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.
Intellia Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.
Intellia Therapeutics currently has a consensus price target of $33.37, indicating a potential upside of 190.67%. ADC Therapeutics has a consensus price target of $7.75, indicating a potential upside of 138.83%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than ADC Therapeutics.
ADC Therapeutics has a net margin of -197.64% compared to Intellia Therapeutics' net margin of -1,154.10%. ADC Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.
88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Intellia Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Intellia Therapeutics and 2 mentions for ADC Therapeutics. Intellia Therapeutics' average media sentiment score of 0.48 beat ADC Therapeutics' score of 0.34 indicating that Intellia Therapeutics is being referred to more favorably in the media.
ADC Therapeutics has higher revenue and earnings than Intellia Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Intellia Therapeutics beats ADC Therapeutics on 10 of the 17 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 7/16/2025 by MarketBeat.com Staff
Free ADCT Stock Alerts